Diagnostic implications of circulating oxidized low density lipoprotein levels as a biochemical risk marker of coronary artery disease

Clinical Biochemistry

Volumn 35, Issue 5, 2002, Pages 347-353

  Suzuki, Toru ^a   Kohno, Hiroaki ^b   Hasegawa, Akira ^c   Toshima, Shunichi ^c   Amaki, Toshihiro ^a   Kurabayashi, Masahiko ^c   Nagai, Ryozo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b Kyowa Medex Co Ltd   (Japan)

^c GUNMA UNIVERSITY   (Japan)

Author keywords

Coronary heart disease; Oxidized LDL; Risk marker; ROC analysis

Indexed keywords

BIOCHEMICAL MARKER; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN A; OXIDIZED LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; BIOLOGICAL MARKER; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL ANALYSIS; BLOOD; CORONARY ARTERY ATHEROSCLEROSIS; MIDDLE AGED; NONPARAMETRIC TEST; OXIDATION REDUCTION REACTION; REGRESSION ANALYSIS; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; BIOLOGICAL MARKERS; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATION-REDUCTION; REGRESSION ANALYSIS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC;

EID: 0036629998     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(02)00326-0     Document Type: Article

References (20)

1. Goldstein J.L., Ho Y.K., Basu S.K., Brown M.S. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA. 76:1979;333-337.
2. Witztum J.L., Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 88:1991;1785-1792.
3. Penn M.S., Chisolm G.M. Oxidized lipoproteins, altered cell function and atherosclerosis. Atherosclerosis. 108:1994;S21-S29.
4. Steinberg D., Lewis A. Conner Memorial Lecture oxidative modification of LDL and atherogenesis . Circulation. 95:1997;1062-1071.
5. Berliner J.A., Navab M., Fogelman A.M., et al. Atherosclerosis basic mechanisms. Oxidation, inflammation, and genetics . Circulation. 91:1995;2488-2496.
6. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol modifications of low-density lipoprotein that increase its atherogenicity . N Engl J Med. 320:1989;915-924.
7. Ross R. The pathogenesis of atherosclerosis a perspective for the 1990s . Nature. 362:1993;801-809.
8. Witztum J.L. Role of oxidised low density lipoprotein in atherogenesis. Br Heart J. 69:1993;S12-S18.
9. Yla-Herttuala S., Palinski W., Rosenfeld M.E., et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 84:1989;1086-1095.
10. McMurray H.F., Parthasarathy S., Steinberg D. Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes. J Clin Invest. 92:1993;1004-1008.
11. Toshima Si, Hasegawa A., Kurabayashi M., et al. Circulating oxidized low density lipoprotein levels a biochemical risk marker for coronary heart disease . Arterioscler Thromb Vasc Biol. 20:2000;2243-2247.
12. Itabe H., Yamamoto H., Imanaka T., et al. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J Lipid Res. 37:1996;45-53.
13. Kohno H., Sueshige N., Oguri K., et al. Simple and practical sandwich-type enzyme immunoassay for human oxidatively modified low density lipoprotein using antioxidized phosphatidylcholine monoclonal antibody and antihuman apolipoprotein-B antibody. Clin Biochem. 33:2000;243-253.
14. Itabe H., Yamamoto H., Suzuki M., et al. Oxidized phosphatidylcholines that modify proteins. J Biol Chem. 271:1996;33208-33217.
15. Itabe H., Takeshima E., Iwasaki H., et al. A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. J Biol Chem. 269:1994;15274-15279.
16. Morrow J.D., Frei B., Longmire A.W., et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med. 332:1995;1198-2003.
17. Holvoet P., Perez G., Zhao Z., Brouwers E., Bernar H., Collen D. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J Clin Invest. 95:1995;2611-2619.
18. Holvoet P., Vanhaecke J., Janssens S., Van de Werf F., Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation. 98:1998;1487-1494.
19. Holvoet P., Donck J., Landeloos M., et al. Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thromb Haemost. 76:1996;663-669.
20. Kotani K., Maekawa M., Kanno T., Kondo A., Toda N., Manabe M. Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum. Biochim Biophys Acta. 1215:1994;121-125.